Back to Search
Start Over
Biologic agents in psoriasis.
- Source :
- Australasian Journal of Dermatology; Nov2006, Vol. 47 Issue 4, p217-230, 14p, 4 Diagrams, 3 Charts
- Publication Year :
- 2006
-
Abstract
- This paper reviews the new biologic agents that selectively block the immunologic steps implicated in the pathogenesis of psoriasis. Four strategies have been targeted: reduction of the number of pathogenic T cells; inhibition of T-cell activation and migration; modulation of the immune system; and blockage of the activity of inflammatory cytokines. There are three classes: monoclonal antibodies, fusion proteins and recombinant cytokines or growth factors. The actions, efficacy and side-effect profile of the biologic agents, alefacept, efalizumab, etanercept and infliximab, are reviewed. [ABSTRACT FROM AUTHOR]
- Subjects :
- T cells
CYTOKINES
CELLULAR immunity
ETANERCEPT
INFLIXIMAB
ANTI-inflammatory agents
Subjects
Details
- Language :
- English
- ISSN :
- 00048380
- Volume :
- 47
- Issue :
- 4
- Database :
- Complementary Index
- Journal :
- Australasian Journal of Dermatology
- Publication Type :
- Academic Journal
- Accession number :
- 22615445
- Full Text :
- https://doi.org/10.1111/j.1440-0960.2006.00286.x